Roquefort Therapeutics PLC financials
Roquefort Therapeutics PLC
254900P4SISIWOR9RH34 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | £0 | £200.0K |
| Cost of sales | £16.0K | £0 |
| Other income | £0 | £0 |
| Administrative expenses | £931.6K | £1.5M |
| Finance costs | £52.8K | £0 |
| Profit before tax | -£1.2M | -£1.9M |
| Income tax expense | -£242.8K | -£187.7K |
| Profit for the year | -£971.8K | -£1.7M |
| Total comprehensive income | -£914.6K | -£1.7M |
| Cash flow statement | ||
| Net cash from operating activities | -£783.7K | -£1.7M |
| Net cash from investing activities | £0 | -£52.6K |
| Purchase of PP&E (capex) | £0 | £54.0K |
| Net cash from financing activities | £584.9K | -£58 |
| Proceeds from borrowings | £584.9K | £0 |
| Net change in cash | -£198.8K | -£1.8M |
| Balance sheet | ||
| Total assets | £5.8M | £6.1M |
| Non-current assets | £5.4M | £5.4M |
| Property, plant & equipment | £44.7K | £50.2K |
| Intangible assets & goodwill | £5.3M | £5.3M |
| Current assets | £362.5K | £694.9K |
| Trade & other receivables | £25.4K | £157.6K |
| Cash & equivalents | £337.1K | £537.3K |
| Total equity | £4.9M | £5.5M |
| Short-term borrowings | £400.1K | £0 |
| Trade & other payables | £179.7K | £307.1K |
| Deferred tax liabilities | £281.9K | £281.9K |
| Derived metrics | ||
| Free cash flow | -£783.7K | -£1.8M |
| Net margin | — | -872.3% |
| Return on equity | -19.9% | -31.7% |
| Cash conversion ratio | 0.81× | 0.99× |
| Capex coverage | — | -32.08× |
| Other reported items | ||
| Adjustments For Decrease Increase In Trade and Other Receivables | £130.4K | -£55.9K |
| Adjustments For Depreciation Expense | £5.4K | £3.9K |
| Adjustments For Finance Costs | £52.8K | £0 |
| Adjustments For Income Tax Expense | £242.8K | £187.7K |
| Adjustments For Increase Decrease In Trade Account Payable | -£121.1K | £27.4K |
| Adjustments For Interest Expense | £44.6K | £58 |
| Adjustments For Interest Income | £0 | £1.5K |
| Adjustments For Sharebased Payments | £21.5K | £10.4K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | £54.6K | £26.5K |
| Depreciation Expense | £5.4K | £3.9K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -£1.4K | £512 |
| Equity and Liabilities | £5.8M | £6.1M |
| Increase Decrease Through Transactions With Owners | £304.0K | £10.4K |
| Interest Expense | £44.9K | £58 |
| Interest Paid Classified As Financing Activities | £0 | £58 |
| Interest Received Classified As Investing Activities | £0 | £1.5K |
| Issue of Equity | £282.6K | £0 |
| Issued Capital | £1.4M | £1.3M |
| Liabilities | £861.7K | £589.0K |
| Merger Reserve | £3.7M | £3.7M |
| Other Comprehensive Income | £57.3K | £27.0K |
| Research and Development Expense | £152.9K | £620.2K |
| Reserve of Exchange Differences On Translation | £69.9K | £12.7K |
| Reserve of Sharebased Payments | £407.0K | £385.5K |
| Retained Earnings | -£5.3M | -£4.3M |
| Revenue From Interest | £0 | £1.5K |
| Share Issue Related Cost | £0 | — |
| Share Premium | £4.6M | £4.4M |
Every line item above is a fact tagged in Roquefort Therapeutics PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.